Dong-A Pharmaceutical said March 10 it has launched “Champu Oral Spray,” which can be used starting in infancy.
The main ingredient is benzydamine hydrochloride, which the company said may help ease inflammation of the throat, mouth and gums and help relieve pain before and after tooth extraction. It can be used by infants and young children under age 6. The spray is used 2 to 6 times a day, with the recommended number of sprays varying by age.
To improve adherence among young children, the product has a strawberry flavor, and the packaging uses a panda character to create a familiar look.
Dongkook Pharmaceutical’s dermacosmetic brand Centellian24 said March 10 it will introduce a limited-edition “Madeca PDRN Sakura Package.”
The set includes four products: Madeca Cream Active Renew PDRN, 360-degree PDRN serum, 360-degree PDRN eye cream, and 360-degree PDRN eye patch.
The limited edition centers on popular items from Centellian24’s PDRN line. It will be unveiled during Qoo10’s “Mega Wari” discount event in Japan, which runs through March 11, and will also be available for purchase through Qoo10’s live broadcast starting at 8 p.m.
HK inno.N said March 10 it held a signing ceremony with Tanabe Pharma Korea for a domestic co-promotion agreement for Badanem tablets (vadadustat), a new drug for renal anemia.
Under the agreement, the two companies will jointly handle sales and marketing in South Korea. They will share responsibility for medical institutions with more than 100 beds, while HK inno.N will manage those with 100 beds or fewer. HK inno.N will also exclusively distribute the product domestically, citing its experience selling kidney-disease products and its nationwide sales network.
Badanem is an oral treatment used to treat anemia in adult patients with chronic kidney disease who are receiving dialysis. It is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor. It comes in 150 mg and 300 mg doses and is taken once daily.
A research team led by Kang Hee-taek, a professor of family medicine at Severance Hospital, and Shim Jae-yong, a professor of family medicine at Gangnam Severance Hospital, said March 10 that greater continuity of care in patients with hypertension or diabetes can reduce medical spending, cardiovascular disease incidence and the risk of death.
The findings suggest that, in managing chronic disease, maintaining an ongoing treatment relationship with a specific medical institution matters more for health outcomes and cost savings than the number of medical visits. The results were published in the latest issue of the international journal Nutrition, Metabolism and Cardiovascular Diseases.
The team treated “continuity of care” — the extent to which a patient consistently receives care from the same institution or clinician — as a key indicator in chronic-disease management and examined how it relates to real-world outcomes.
In patients with hypertension, those with higher continuity of care had fewer hospitalizations among both men and women, and women also had fewer emergency room visits. Total hypertension-related medical costs, costs per visit and annual medical costs all tended to be lower in the high-continuity group. Differences were especially clear in the risk of cardiovascular disease, and similar results were found among patients with diabetes.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.